Floatz logo

TIPIRACIL

Gastroesophageal Adenocarcinoma

AbbVieSmall moleculePhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

40 Active assets in the Gastroesophageal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Eloxatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
Pembrolizumab
Diwakar Davar
Phase 3BB
Nivolumab
Memorial Sloan Kettering Cancer Center
Phase 2BB
TRASTUZUMAB
UNICANCER
Phase 3BB
Capecitabine
Shanghai Zhongshan Hospital
Phase 3B

View all 50 →

Same molecule, other indications

TIPIRACIL is also rated in:

colorectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
69 / 100
View asset →
rectal cancerDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →